Melanoma vaccine - Enara Bio
Latest Information Update: 28 Dec 2023
At a glance
- Originator Ervaxx
- Developer Enara Bio
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in United Kingdom (Parenteral)